Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 7 de 7
Filter
Add more filters










Database
Language
Publication year range
1.
Front Pediatr ; 10: 778585, 2022.
Article in English | MEDLINE | ID: mdl-35223691

ABSTRACT

PURPOSE: The purpose of this study is to review the neonatal and early childhood course of children who were treated with intravitreal bevacizumab for APROP and identify any long term limitations these children face years after treatment. METHODS: This retrospective consecutive case series reviewed both ophthalmologic and pediatric medical records to determine ocular and neurologic function following treatment with a single injection of intravitreal bevacizumab (IVB) for APROP. Patient records were reviewed to identify the gestational age, average birth weight, gender, post-menstrual age (PMA) at the time of injection, regression status, rescue therapy events, final visual acuity, final refraction, ophthalmologic diagnoses and complications, neurologic diagnoses, and duration of follow up. RESULTS: The study included 43 eyes from 13 male and 9 female children. The average gestational age was 24 weeks and average birth weight was 625.2 grams. The average follow-up was 4.08 years (range: 1.85-7.36 years). The average PMA at time of bevacizumab injection was 35.59 weeks. Thirty-five eyes eventually received laser photocoagulation at an average PMA of 53.17 weeks. All eyes in this study demonstrated regression without progression to retinal detachment. At last follow up, 67% (29/43) of eyes were able to discern letters or shapes, with an average visual acuity of 20/37. 16 (72%) children were diagnosed with perinatal neurological disorders. 59% (n = 13) developed chronic neurological impairment, 77% (n = 10) of whom developed neurodevelopmental delay. Several infants were diagnosed with endocrine disease or genetic syndromes. CONCLUSIONS: Extreme prematurity is associated with significant morbidity. Nearly all infants (92%) who developed chronic neurologic disease were diagnosed with neurologic disease during the perinatal period. Intravitreal bevacizumab, often with adjuvant photocoagulation, led to regression without detachment in 100% of eyes, with most verbal children retaining functional vision.

2.
Ophthalmol Retina ; 5(1): 4-8, 2021 01.
Article in English | MEDLINE | ID: mdl-32688085

ABSTRACT

PURPOSE: To investigate the rate of return to the operating room after vitrectomy surgery for vitreous opacities. DESIGN: Retrospective registry cohort. PARTICIPANTS: Individuals receiving care in ophthalmology practices participating in the Intelligent Research in Sight (IRIS®) Registry. METHODS: Data from the IRIS Registry were analyzed for patients who underwent vitrectomy for vitreous opacities. Cases were identified by the combination of International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), and International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), codes (379.21, 379.22, 379.24, and 379.25), and a Current Procedural Terminology (CPT) code for vitrectomy surgery. MAIN OUTCOME MEASURES: The number and percentage of eyes that underwent additional eye surgery within 1 year after vitrectomy for vitreous opacities were identified, as was the nature of the additional procedures per CPT code. RESULTS: Fifty thousand eight hundred thirty-six eyes that underwent vitrectomy surgery linked to one of the ICD-9-CM or ICD-10-CM codes for vitreous opacities were identified. In 17 615 eyes, the surgery was linked to the vitreous opacities code exclusively, and not to epiretinal membrane or macular hole codes. Of these, 2187 eyes (12.4%) returned to the operating room for cataract surgery, and 643 eyes (3.7%) returned to the operating room for a noncataract procedure. Four hundred fifty-seven eyes (2.6%) returned to the operating room for retinal detachment repair. CONCLUSIONS: In the IRIS Registry, eyes undergoing vitrectomy for vitreous opacities returned to the operating room for an ophthalmic surgery other than cataract extraction 3.7% of the time, and retinal detachment repair was performed 2.6% of the time.


Subject(s)
Eye Diseases/surgery , Operating Rooms/statistics & numerical data , Registries , Visual Acuity , Vitrectomy/methods , Vitreous Body/surgery , Eye Diseases/diagnosis , Follow-Up Studies , Humans , Postoperative Complications , Reoperation/statistics & numerical data , Retrospective Studies , Vitreous Body/diagnostic imaging
3.
Retina ; 41(4): 706-710, 2021 Apr 01.
Article in English | MEDLINE | ID: mdl-32796444

ABSTRACT

PURPOSE: To assess the safety and efficacy of less dense panretinal photocoagulation after intravitreal bevacizumab in aggressive posterior retinopathy of prematurity infants. METHODS: Retrospective consecutive case series of premature infants diagnosed with aggressive posterior retinopathy of prematurity between August 2012 and November 2015 who received intravitreal bevacizumab with subsequent modified indirect diode laser panretinal photocoagulation for reactivation or incomplete vascularization. Main outcome measures included postprocedural reactivation, retinal detachments, or anterior segment ischemia. RESULTS: Sixty-one eyes of 31 premature infants were identified. The average gestational age was 24 ± 2.2 weeks (range 22-27), and the average birth weight was 661.5 ± 167.1 g (range 340.0-930.5 g). The average follow-up was 3.9 ± 1.3 years (range 1.3-5.4 years). At the last follow-up, no patient had experienced postlaser reactivation, retinal detachments, anterior segment ischemia, or other laser complications. CONCLUSION: This study suggests that nonconfluent panretinal photocoagulation for aggressive posterior retinopathy of prematurity infants who have received intravitreal bevacizumab may be safe and effective. This study's strengths include a sizeable sample size, long-term follow-up of nearly 4 years, and consistency in treatment among patients by a single, experienced retinopathy of prematurity specialist.


Subject(s)
Angiogenesis Inhibitors/therapeutic use , Bevacizumab/therapeutic use , Laser Coagulation , Retinopathy of Prematurity/surgery , Birth Weight , Combined Modality Therapy , Female , Follow-Up Studies , Gestational Age , Humans , Infant , Infant, Newborn , Infant, Premature , Intravitreal Injections , Lasers, Semiconductor , Male , Retinopathy of Prematurity/drug therapy , Retrospective Studies , Treatment Outcome , Vascular Endothelial Growth Factor A/antagonists & inhibitors
4.
Am J Ophthalmol Case Rep ; 15: 100515, 2019 Sep.
Article in English | MEDLINE | ID: mdl-31341998

ABSTRACT

PURPOSE: To describe an unusual case of Bartonella henselae neuroretinitis complicated by macular hole (MH) development. OBSERVATIONS: A full-thickness macular hole developed in a 12-year-old boy in association with serology-confirmed Bartonella henselae neuroretinitis. Following a period of observation, the MH closed without intervention. CONCLUSION AND IMPORTANCE: MH may occur as a complication of neuroretinitis secondary to Cat-Scratch Disease.

5.
Ocul Oncol Pathol ; 3(4): 279-282, 2017 Nov.
Article in English | MEDLINE | ID: mdl-29344481

ABSTRACT

Choroidal melanoma is the most common primary intraocular malignancy, yet metastatic disease remains the most common malignancy of the eye. Differentiating these entities is essential as treatment, systemic associations, and prognosis vary dramatically between the two. Established diagnostic criteria are accurate for the diagnosis of uveal melanoma. Yet, metastatic disease may be misdiagnosed as a uveal melanoma in rare cases. We report a case of metastatic clear-cell renal cell carcinoma masquerading as uveal melanoma. A 73-year-old Caucasian man with a history of renal cell carcinoma presented with a 15 × 12 × 7 mm homogenous, pigmented, and acoustically hollow mass without hemorrhage or exudation. The patient was initially treated with plaque radiotherapy with good tumor regression. However, the patient developed pain and vision loss due to total exudative retinal detachment. Subsequent enucleation allowed histopathologic confirmation of clear-cell renal cell carcinoma. Nine years following enucleation, the patient remains in complete remission without evidence of other systemic metastases. Renal cell carcinoma should be considered when evaluating patients with probable uveal melanoma. Delayed-onset ocular metastasis from renal cell carcinoma exhibits an atypical clinical course with the possibility of durable remission following enucleation.

6.
Laryngoscope ; 124(7): 1653-8, 2014 Jul.
Article in English | MEDLINE | ID: mdl-24281875

ABSTRACT

OBJECTIVES/HYPOTHESIS: To evaluate vocal outcomes in 10 patients 1 year after autologous transplantation of temporalis fascia into Reinke's space (ATFV) for vocal fold scar and sulcus vocalis. STUDY DESIGN: Retrospective, clinical case series. METHODS: Subjective and objective evaluation was performed 12 months after surgery using laryngovideostroboscopy (LVS) in all patients, the Voice Handicap Index-10 (VHI-10) in seven patients, GRBAS (grade, roughness, breathiness, asthenia, strain) scale in nine patients, and noise-to-harmonics ratio (NHR), phonatory range (PR) and maximum phonation time (MPT) in six patients. RESULTS: LVS improved in all but one patient. A significant decrease was noted in the GRBAS subscales grade, roughness, asthenia, and strain (P<.05). Breathiness was almost significant, with a P value of .052. There was an average decrease in the VHI-10 of 8.14 (P=.032). NHR, MPT, and PR did not statistically improve. CONCLUSIONS: ATFV for vocal fold scar and sulcus vocalis results in significant subjective vocal improvement that persists at least 1 year after surgery. LEVEL OF EVIDENCE: 4.


Subject(s)
Cicatrix/surgery , Fascia/transplantation , Laryngeal Muscles/transplantation , Phonation , Plastic Surgery Procedures/methods , Vocal Cords/surgery , Voice Disorders/surgery , Adult , Cicatrix/complications , Cicatrix/pathology , Female , Follow-Up Studies , Humans , Male , Middle Aged , Retrospective Studies , Transplantation, Autologous , Treatment Outcome , Vocal Cords/physiopathology , Voice Disorders/etiology , Voice Disorders/physiopathology , Voice Quality
7.
Am J Ophthalmol ; 148(6): 837-43, 2009 Dec.
Article in English | MEDLINE | ID: mdl-19800608

ABSTRACT

PURPOSE: To examine the complications encountered after Descemet stripping automated endothelial keratoplasty (DSAEK) at one institution. DESIGN: Retrospective case review. METHODS: The first 126 consecutive DSAEKs done at the New York Eye and Ear Infirmary from March 1, 2006 to March 1, 2008 were reviewed. A total of 126 eyes of 113 patients underwent DSAEK. All cases were included regardless of outcome. All complications intraoperatively and postoperatively were recorded. RESULTS: Graft detachment was the most common complication, occurring in 22 eyes (17.5%); 17 of these (77%) were successfully repositioned. Idiopathic graft failure occurred in 15 eyes (6%). Other visually significant complications included graft rejection (2 eyes), choroidal effusion (2 eyes), epithelial ingrowth (2 eyes), endophthalmitis (1 eye), pupillary block (1 eye), and suture abscess (1 eye). Twenty-four eyes had non-visually significant complications including decentered lenticles, interface fibers, partial peripheral detachments, retained Descemet membrane, and eccentric trephination. CONCLUSIONS: While DSAEK is a viable alternative to penetrating keratoplasty, serious complications may still occur postoperatively. While certain rare complications like endophthalmitis, epithelial ingrowth, and suture abscess may affect vision, more common complications such as decentered lenticles and partial peripheral detachments are less likely to affect visual outcome.


Subject(s)
Corneal Transplantation/methods , Descemet Membrane/surgery , Endothelium, Corneal/transplantation , Intraoperative Complications , Postoperative Complications , Vision Disorders/etiology , Aged , Corneal Diseases/surgery , Female , Humans , Male , Retrospective Studies , Visual Acuity
SELECTION OF CITATIONS
SEARCH DETAIL
...